We are live on ! Find out more
EP

Eversept Partners Portfolio holdings

AUM $1.93B
1-Year Est. Return 160.8%
This Fund
S&P 500
This Quarter Est. Return
+7.72%
1 Year Est. Return
+160.8%
3 Year Est. Return
+321.09%
5 Year Est. Return
+420.29%
10 Year Est. Return
–
AUM
$357M
AUM Growth
+$14.3M
Cap. Flow
-$377K
Cap. Flow %
-0.11%
Top 10 Hldgs %
60.48%
Holding
73
New
21
Increased
19
Reduced
16
Closed
11

Top Buys

Rank Stock Value
1
ENSG icon
The Ensign Group
ENSG
+$7.79M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$6.69M
3
BOLD
Audentes Therapeutics, Inc
BOLD
+$6.13M
4
ILMN icon
Illumina
ILMN
+$5.94M
5
CNC icon
Centene
CNC
+$4.1M

Top Sells

Rank Stock Value
1
NUVA
NuVasive, Inc.
NUVA
+$14.1M
2
AMRN
Amarin Corp
AMRN
+$9.2M
3
SRPT icon
Sarepta Therapeutics
SRPT
+$8.15M
4
ABMD
Abiomed Inc
ABMD
+$7.81M
5
AERI
Aerie Pharmaceuticals
AERI
+$5.45M

Sector Composition

Rank Sector Weight
1 Healthcare 82.49%
2 Industrials 9.51%
3 Financials 4.31%
4 Miscellaneous 1.99%
5 Real Estate 1.7%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AKRX
51
DELISTED
Akorn Inc
AKRX
$678K 0.19%
+131,640
New +$507K
DRNA
52
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$647K 0.18%
41,074
– –
FOMX
53
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$627K 0.18%
263,390
-31,270
-11% -$93.4K
CBAY
54
DELISTED
Cymabay Therapeutics
CBAY
$604K 0.17%
84,296
-23,000
-21% -$260K
ALBO
55
DELISTED
Albireo Pharma Inc
ALBO
$581K 0.16%
18,029
– –
SVRA icon
56
Savara
SVRA
$1.08B
$574K 0.16%
+242,143
New +$2.15M
SCPH
57
DELISTED
scPharmaceuticals
SCPH
$556K 0.16%
+174,297
New +$570K
PFNX
58
DELISTED
Pfenex Inc.
PFNX
$546K 0.15%
80,968
+5,268
+7% +$33.7K
OTIC
59
DELISTED
Otonomy, Inc.
OTIC
$535K 0.15%
194,429
+14,329
+8% +$38.2K
BCRX icon
60
CALL
BioCryst Pharmaceuticals
BCRX
$2.51B
$386K 0.11%
+101,800
New +$613K
CYCN icon
61
Cyclerion Therapeutics
CYCN
$17.7M
$217K 0.06%
+946
New +$268K
NGNE icon
62
Neurogene
NGNE
$732M
$174K 0.05%
3,686
– –
CHRS icon
63
Coherus Oncology
CHRS
$218M
– –
-120,036
Closed -$1.64M
CRSP icon
64
CRISPR Therapeutics
CRSP
$5.58B
– –
-42,400
Closed -$1.51M
IRWD icon
65
Ironwood Pharmaceuticals
IRWD
$682M
– –
-233,667
Closed -$2.65M
NVAX icon
66
PUT
Novavax
NVAX
$1.53B
– –
-7,255
Closed -$79.9K
OPCH icon
67
Option Care Health
OPCH
$3.58B
– –
-30,753
Closed -$246K
ICPT
68
CALL
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
– –
-43,800
Closed -$4.9M
CNCE
69
CALL
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
– –
-2,300
Closed -$27.8K
CNCE
70
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
– –
-47,154
Closed -$569K
ABMD
71
DELISTED
Abiomed Inc
ABMD
– –
-27,339
Closed -$7.81M
AERI
72
DELISTED
Aerie Pharmaceuticals
AERI
– –
-114,779
Closed -$5.45M
ARRY
73
DELISTED
Array Biopharma Inc
ARRY
– –
-214,112
Closed -$5.22M
1 2
3

Similar funds

SWM
Segment Wealth Management Houston, Texas $1.93B AUM 29.24% 1-Year Est. Return
RIA
Regal Investment Advisors Kentwood, Michigan $1.92B AUM 23.13% 1-Year Est. Return
SI
Standard Investments New York $1.93B AUM 6.23% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $1.92B AUM 45.54% 1-Year Est. Return
DCP
Distillate Capital Partners Chicago, Illinois $1.92B AUM 5.31% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
GIA
Guyasuta Investment Advisors Pittsburgh, Pennsylvania $1.94B AUM 32.92% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return

Eversept Partners's Q2 2019 Portfolio in Review

As of Q2 2019, Eversept Partners held 73 positions worth $357M, up 4.2% from $343M the previous quarter. Its ten largest holdings account for 60% of the portfolio.

Eversept Partners's Q2 2019 filing shows 21 new, 19 increased, 16 reduced and 11 closed positions. Its largest new stake was Alnylam Pharmaceuticals: 87,140 shares worth $6.32M. The largest sale was NuVasive, Inc., an estimated $14.1M.

By sector, the portfolio is most concentrated in Healthcare at 82% of assets, down from 86% a quarter earlier, followed by Industrials and Financials.

  • Eversept Partners's largest Q2 2019 buy was Alnylam Pharmaceuticals: 87,140 shares worth $6.32M.
  • Eversept Partners added most to The Ensign Group in Q2 2019, an estimated $7.79M increase.
  • Eversept Partners's biggest Q2 2019 reduction was NuVasive, Inc., cutting an estimated $14.1M.
  • Eversept Partners fully exited Abiomed Inc in Q2 2019, selling an estimated $7.81M.
  • Eversept Partners's ten largest holdings make up 60% of its $357M portfolio in Q2 2019.
  • Eversept Partners opened 21 new positions and closed 11 in Q2 2019.
  • Eversept Partners's portfolio value rose 4.2% quarter-over-quarter to $357M.

Based on Eversept Partners's 13F filing for Q2 2019, filed 13 Aug 2019.